Is healthcare investment really best left until after the US election?
Biotech has fallen
Since its peak in July 2015, the NASDAQ Biotechnology index has fallen, in dollar terms, by 30%, with much of this fall happening in the first two months of the year. Large US biotech companies are now exceptionally good value and the long-term growth prospects for the sector remain intact.
While the biotech sector was swept up in the negative market sentiment, concerns over the outlook for drug pricing in the US also played a role in the sector's re-rating. Both front-runners – Hillary...
More on Specialist
Back to Top
